). Both preferred outcomes and surrogate markers
are used to measure the "worthiness" or benefit of CSF therapy. Duration of hospitalization is an indirect measure of severity of il1ness and swiftness of recovery from neutropenia and infectious complications. In general, the fewer the hospital days, the lower the treatment costs; therefore, duration of hospitalization also is used as an economic outcome. Other economic outcomes include resource utilization and total cost of patient care.
.
Outcomes Data Documented for CSFs
Numerous clinical trials have documented outcomes in patients treated with CSFs. The most frequently reported outcome in these studies was the duration of neutropenia and the most infrequent was survival. The most powerful outcomes reported are surviva1, incidence of infection, and duration of hospitalization (see Table 3 , page 146).
Chemotherapy-Induced Neutropenia
There are only two randomized, clinical trials published in full that directly compare outcomes in patients treated with CSFs commercially available in the U.S. Both studies were conducted in patients with chemotherapy-induced neutropenia.20.21 The first study was designed to compare the tolerability of theCSFs. In this prospective, randomized, double-blind study, 144 patients receiving myelosuppressive chemotherapy were treated with sargramostim or filgrastim for prophylaxis or treatment of chemotherapy-induced neutropenia. Both CSFs were well tolerated and had comparable safety profiJes: The on1y statistically significant difference between treatments was a slightly higher incidence of 10w-grade fever (temperature <38"C) in patients treated with sargramostim (p=O.O 1); however, there was no difference in the incidence of clinically significant fever (~380C). Both treatment groups also had a similar number of days of CSF treatment, hospitalization, and antibiotics.2o
The second study was designed to evaluate efficacy21 A total of 181 cancer patients were treated in the community setting for In placebo-controlled studies in patients receiving standard-dose chemotherapy, filgrastim significantly reduced the incidence of febrile neutropenia, the duration of neutropenia, the percentage of patients requiring antibiotics, the number of days of antibiotic therapy, and the incidence of mucositis. D. 22 Published literature on CSF outcomes offers powerful documentation that the benefits associated with the use of CSFs are limited to certain populations and that sargramostim and filgrastim can be differentiated based on outcomes. Both CSFs appear to offer similar benefits in chemotherapy-induced neutropenia, autologous BMT, and PBPC transplantation. Sargramostim offers superior outcomes in allogeneic BMT, BMT graft failure, and AML. Filgrastim demonstrates benefit in severe chronic neutropenia. These differences in outcomes should be used to make decisions regarding selection of CSFs in specific patient populations. .
